Another marker that is reported to be preferentially overexpressed in CD34+CD38− AML cells is CD123, and its expression serves as a clinical marker for adverse patient outcome; it is potentially mediated by mechanisms involving STAT5 activation [22,23,24,25]. This evidence concerns the gene CD38 and acute myeloid leukemia.